<DOC>
	<DOCNO>NCT02474563</DOCNO>
	<brief_summary>The purpose study assess 2-year progression-free survival rate .</brief_summary>
	<brief_title>Observational Study Evaluate Efficacy Safety Bortezomib , Melphalan , Prednisone ( VMP ) Participants With Multiple Myeloma</brief_title>
	<detailed_description>This prospective , open-label , multicenter , observational study . Participants receive bortezomib , Melphalan , Prednisone ( VMP ) therapy Multiple myeloma ( MM ) eligible autologous stem cell transplantation enrol study . The study consist Screening phase ; VMP therapy phase ( 9cycles ) ; Follow-up phase ( 2 year day first cycle start ) . Participants visited institution evaluation 2 year date baseline evaluation first VMP administration ( duration treatment , 9 cycle ; follow-up visit , every 3 month end treatment ) . Participants receive VMP therapy primarily evaluate 2-year progression-free survival rate . Participants safety monitor throughout study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Participants na√Øve chemotherapy multiple myeloma eligible autologous stem cell transplantation Participants symptomatic multiple myeloma : ) Intramedullary monoclonal plasma cell great equal ( &gt; = ) 10 % histologically confirm plasmacytoma ; b ) Presence monoclonal protein serum urine ; c ) Myelomarelated organ impairment define protocol Participants presence illness detectable definition define protocol Postmenopausal , sterilize sexually inactive woman , include woman childbearing potential exercise effective contraceptive measure clinical trial Participants previous experience receive therapy multiple myeloma ( exclude radiotherapy dexamethasone &lt; 160mg total ) Participants severe peripheral neuropathy ( Grade &gt; = 2 NCI CTC version 4.0 ) Pregnant breastfeed mother Participants mental illness interfere his/her cooperation therapy monitoring condition clinical trial Participants serious medical condition ( uncontrolled hypertension , diabetes mellitus active infection )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Prednisone</keyword>
</DOC>